- IBDEI1XU ; ; 04-FEB-2020
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,30953,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30953,1,3,0)
- ;;=3^Type 1 DM w/ Diabetic Nephropathy
- ;;^UTILITY(U,$J,358.3,30953,1,4,0)
- ;;=4^E10.21
- ;;^UTILITY(U,$J,358.3,30953,2)
- ;;=^5002589
- ;;^UTILITY(U,$J,358.3,30954,0)
- ;;=E10.22^^123^1598^16
- ;;^UTILITY(U,$J,358.3,30954,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30954,1,3,0)
- ;;=3^Type 1 DM w/ Diabetic CKD
- ;;^UTILITY(U,$J,358.3,30954,1,4,0)
- ;;=4^E10.22
- ;;^UTILITY(U,$J,358.3,30954,2)
- ;;=^5002590
- ;;^UTILITY(U,$J,358.3,30955,0)
- ;;=D59.3^^123^1598^3
- ;;^UTILITY(U,$J,358.3,30955,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30955,1,3,0)
- ;;=3^Hemolytic-uremic syndrome
- ;;^UTILITY(U,$J,358.3,30955,1,4,0)
- ;;=4^D59.3
- ;;^UTILITY(U,$J,358.3,30955,2)
- ;;=^55823
- ;;^UTILITY(U,$J,358.3,30956,0)
- ;;=D69.0^^123^1598^4
- ;;^UTILITY(U,$J,358.3,30956,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30956,1,3,0)
- ;;=3^Henoch-Schoeniein Purpura
- ;;^UTILITY(U,$J,358.3,30956,1,4,0)
- ;;=4^D69.0
- ;;^UTILITY(U,$J,358.3,30956,2)
- ;;=^5002365
- ;;^UTILITY(U,$J,358.3,30957,0)
- ;;=M30.0^^123^1598^12
- ;;^UTILITY(U,$J,358.3,30957,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30957,1,3,0)
- ;;=3^Polyarteritis nodosa
- ;;^UTILITY(U,$J,358.3,30957,1,4,0)
- ;;=4^M30.0
- ;;^UTILITY(U,$J,358.3,30957,2)
- ;;=^5011738
- ;;^UTILITY(U,$J,358.3,30958,0)
- ;;=M31.0^^123^1598^5
- ;;^UTILITY(U,$J,358.3,30958,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30958,1,3,0)
- ;;=3^Hypersensitivity angiitis
- ;;^UTILITY(U,$J,358.3,30958,1,4,0)
- ;;=4^M31.0
- ;;^UTILITY(U,$J,358.3,30958,2)
- ;;=^60279
- ;;^UTILITY(U,$J,358.3,30959,0)
- ;;=M31.31^^123^1598^22
- ;;^UTILITY(U,$J,358.3,30959,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30959,1,3,0)
- ;;=3^Wegener's granulomatosis w/ renal involvement
- ;;^UTILITY(U,$J,358.3,30959,1,4,0)
- ;;=4^M31.31
- ;;^UTILITY(U,$J,358.3,30959,2)
- ;;=^5011745
- ;;^UTILITY(U,$J,358.3,30960,0)
- ;;=N28.89^^123^1598^6
- ;;^UTILITY(U,$J,358.3,30960,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30960,1,3,0)
- ;;=3^Kidney & Ureter Disorders,Oth Specified
- ;;^UTILITY(U,$J,358.3,30960,1,4,0)
- ;;=4^N28.89
- ;;^UTILITY(U,$J,358.3,30960,2)
- ;;=^88007
- ;;^UTILITY(U,$J,358.3,30961,0)
- ;;=E85.4^^123^1598^11
- ;;^UTILITY(U,$J,358.3,30961,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30961,1,3,0)
- ;;=3^Organ-limited amyloidosis
- ;;^UTILITY(U,$J,358.3,30961,1,4,0)
- ;;=4^E85.4
- ;;^UTILITY(U,$J,358.3,30961,2)
- ;;=^5003017
- ;;^UTILITY(U,$J,358.3,30962,0)
- ;;=M32.14^^123^1598^2
- ;;^UTILITY(U,$J,358.3,30962,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30962,1,3,0)
- ;;=3^Glomerular disease in systemic lupus erythematosus
- ;;^UTILITY(U,$J,358.3,30962,1,4,0)
- ;;=4^M32.14
- ;;^UTILITY(U,$J,358.3,30962,2)
- ;;=^5011757
- ;;^UTILITY(U,$J,358.3,30963,0)
- ;;=M32.15^^123^1598^15
- ;;^UTILITY(U,$J,358.3,30963,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30963,1,3,0)
- ;;=3^Tubulo-interstitial neuropathy in SLE
- ;;^UTILITY(U,$J,358.3,30963,1,4,0)
- ;;=4^M32.15
- ;;^UTILITY(U,$J,358.3,30963,2)
- ;;=^5011758
- ;;^UTILITY(U,$J,358.3,30964,0)
- ;;=M34.0^^123^1598^13
- ;;^UTILITY(U,$J,358.3,30964,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30964,1,3,0)
- ;;=3^Progressive systemic sclerosis
- ;;^UTILITY(U,$J,358.3,30964,1,4,0)
- ;;=4^M34.0
- ;;^UTILITY(U,$J,358.3,30964,2)
- ;;=^5011778
- ;;^UTILITY(U,$J,358.3,30965,0)
- ;;=M31.1^^123^1598^14
- ;;^UTILITY(U,$J,358.3,30965,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,30965,1,3,0)
- ;;=3^Thrombotic Microangiopathy
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XU 3796 printed Jan 18, 2025@03:19:07 Page 2
- IBDEI1XU ; ; 04-FEB-2020
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,30953,1,0)
- +2 ;;=^358.31IA^4^2
- +3 ;;^UTILITY(U,$J,358.3,30953,1,3,0)
- +4 ;;=3^Type 1 DM w/ Diabetic Nephropathy
- +5 ;;^UTILITY(U,$J,358.3,30953,1,4,0)
- +6 ;;=4^E10.21
- +7 ;;^UTILITY(U,$J,358.3,30953,2)
- +8 ;;=^5002589
- +9 ;;^UTILITY(U,$J,358.3,30954,0)
- +10 ;;=E10.22^^123^1598^16
- +11 ;;^UTILITY(U,$J,358.3,30954,1,0)
- +12 ;;=^358.31IA^4^2
- +13 ;;^UTILITY(U,$J,358.3,30954,1,3,0)
- +14 ;;=3^Type 1 DM w/ Diabetic CKD
- +15 ;;^UTILITY(U,$J,358.3,30954,1,4,0)
- +16 ;;=4^E10.22
- +17 ;;^UTILITY(U,$J,358.3,30954,2)
- +18 ;;=^5002590
- +19 ;;^UTILITY(U,$J,358.3,30955,0)
- +20 ;;=D59.3^^123^1598^3
- +21 ;;^UTILITY(U,$J,358.3,30955,1,0)
- +22 ;;=^358.31IA^4^2
- +23 ;;^UTILITY(U,$J,358.3,30955,1,3,0)
- +24 ;;=3^Hemolytic-uremic syndrome
- +25 ;;^UTILITY(U,$J,358.3,30955,1,4,0)
- +26 ;;=4^D59.3
- +27 ;;^UTILITY(U,$J,358.3,30955,2)
- +28 ;;=^55823
- +29 ;;^UTILITY(U,$J,358.3,30956,0)
- +30 ;;=D69.0^^123^1598^4
- +31 ;;^UTILITY(U,$J,358.3,30956,1,0)
- +32 ;;=^358.31IA^4^2
- +33 ;;^UTILITY(U,$J,358.3,30956,1,3,0)
- +34 ;;=3^Henoch-Schoeniein Purpura
- +35 ;;^UTILITY(U,$J,358.3,30956,1,4,0)
- +36 ;;=4^D69.0
- +37 ;;^UTILITY(U,$J,358.3,30956,2)
- +38 ;;=^5002365
- +39 ;;^UTILITY(U,$J,358.3,30957,0)
- +40 ;;=M30.0^^123^1598^12
- +41 ;;^UTILITY(U,$J,358.3,30957,1,0)
- +42 ;;=^358.31IA^4^2
- +43 ;;^UTILITY(U,$J,358.3,30957,1,3,0)
- +44 ;;=3^Polyarteritis nodosa
- +45 ;;^UTILITY(U,$J,358.3,30957,1,4,0)
- +46 ;;=4^M30.0
- +47 ;;^UTILITY(U,$J,358.3,30957,2)
- +48 ;;=^5011738
- +49 ;;^UTILITY(U,$J,358.3,30958,0)
- +50 ;;=M31.0^^123^1598^5
- +51 ;;^UTILITY(U,$J,358.3,30958,1,0)
- +52 ;;=^358.31IA^4^2
- +53 ;;^UTILITY(U,$J,358.3,30958,1,3,0)
- +54 ;;=3^Hypersensitivity angiitis
- +55 ;;^UTILITY(U,$J,358.3,30958,1,4,0)
- +56 ;;=4^M31.0
- +57 ;;^UTILITY(U,$J,358.3,30958,2)
- +58 ;;=^60279
- +59 ;;^UTILITY(U,$J,358.3,30959,0)
- +60 ;;=M31.31^^123^1598^22
- +61 ;;^UTILITY(U,$J,358.3,30959,1,0)
- +62 ;;=^358.31IA^4^2
- +63 ;;^UTILITY(U,$J,358.3,30959,1,3,0)
- +64 ;;=3^Wegener's granulomatosis w/ renal involvement
- +65 ;;^UTILITY(U,$J,358.3,30959,1,4,0)
- +66 ;;=4^M31.31
- +67 ;;^UTILITY(U,$J,358.3,30959,2)
- +68 ;;=^5011745
- +69 ;;^UTILITY(U,$J,358.3,30960,0)
- +70 ;;=N28.89^^123^1598^6
- +71 ;;^UTILITY(U,$J,358.3,30960,1,0)
- +72 ;;=^358.31IA^4^2
- +73 ;;^UTILITY(U,$J,358.3,30960,1,3,0)
- +74 ;;=3^Kidney & Ureter Disorders,Oth Specified
- +75 ;;^UTILITY(U,$J,358.3,30960,1,4,0)
- +76 ;;=4^N28.89
- +77 ;;^UTILITY(U,$J,358.3,30960,2)
- +78 ;;=^88007
- +79 ;;^UTILITY(U,$J,358.3,30961,0)
- +80 ;;=E85.4^^123^1598^11
- +81 ;;^UTILITY(U,$J,358.3,30961,1,0)
- +82 ;;=^358.31IA^4^2
- +83 ;;^UTILITY(U,$J,358.3,30961,1,3,0)
- +84 ;;=3^Organ-limited amyloidosis
- +85 ;;^UTILITY(U,$J,358.3,30961,1,4,0)
- +86 ;;=4^E85.4
- +87 ;;^UTILITY(U,$J,358.3,30961,2)
- +88 ;;=^5003017
- +89 ;;^UTILITY(U,$J,358.3,30962,0)
- +90 ;;=M32.14^^123^1598^2
- +91 ;;^UTILITY(U,$J,358.3,30962,1,0)
- +92 ;;=^358.31IA^4^2
- +93 ;;^UTILITY(U,$J,358.3,30962,1,3,0)
- +94 ;;=3^Glomerular disease in systemic lupus erythematosus
- +95 ;;^UTILITY(U,$J,358.3,30962,1,4,0)
- +96 ;;=4^M32.14
- +97 ;;^UTILITY(U,$J,358.3,30962,2)
- +98 ;;=^5011757
- +99 ;;^UTILITY(U,$J,358.3,30963,0)
- +100 ;;=M32.15^^123^1598^15
- +101 ;;^UTILITY(U,$J,358.3,30963,1,0)
- +102 ;;=^358.31IA^4^2
- +103 ;;^UTILITY(U,$J,358.3,30963,1,3,0)
- +104 ;;=3^Tubulo-interstitial neuropathy in SLE
- +105 ;;^UTILITY(U,$J,358.3,30963,1,4,0)
- +106 ;;=4^M32.15
- +107 ;;^UTILITY(U,$J,358.3,30963,2)
- +108 ;;=^5011758
- +109 ;;^UTILITY(U,$J,358.3,30964,0)
- +110 ;;=M34.0^^123^1598^13
- +111 ;;^UTILITY(U,$J,358.3,30964,1,0)
- +112 ;;=^358.31IA^4^2
- +113 ;;^UTILITY(U,$J,358.3,30964,1,3,0)
- +114 ;;=3^Progressive systemic sclerosis
- +115 ;;^UTILITY(U,$J,358.3,30964,1,4,0)
- +116 ;;=4^M34.0
- +117 ;;^UTILITY(U,$J,358.3,30964,2)
- +118 ;;=^5011778
- +119 ;;^UTILITY(U,$J,358.3,30965,0)
- +120 ;;=M31.1^^123^1598^14
- +121 ;;^UTILITY(U,$J,358.3,30965,1,0)
- +122 ;;=^358.31IA^4^2
- +123 ;;^UTILITY(U,$J,358.3,30965,1,3,0)
- +124 ;;=3^Thrombotic Microangiopathy